Medical technology company Polarcool reports higher revenue and an increased operating loss in the second quarter of 2026 compared with the same quarter last year.Net sales rose 14.3 percent to SEK 0.8 million (0.7).Operating profit amounted to SEK -4.9 million (-3.9). Profit after tax amounted to SEK -4.9 million (-3.9). Earnings per share amounted to SEK -0.42 (-0.70).- Polarcool is facing an important strategic shift in which we are placing our greatest focus on the North American market. Here, we see significantly greater commercial potential for Polarcap than in Europe. In parallel with continuing our work on the regulatory processes in the US and Canada, we have held concrete discussions with several prominent sports organizations, such as clubs and entities affiliated with the NHL, NFL and leading American sports universities. Our objective remains to be able to launch Polarcap in North America during 2026, comments CEOErik Andersson in the interim report. On August 4, the company held an extraordinary general meeting that decided to approve the board's decision to apply for delisting from Spotlight Stock Market. The delisting is expected to take place in October. The company's ambition is to work toward a listing in the US within 18–24 months.As previously announced, Polarcool raised a bridge loan of SEK 4.0 million in mid-July. Polarcool, SEK millionQ2-2026Q2-2025ChangeNet sales0.80.714.3%Operating profit-4.9-3.9Net profit-4.9-3.9Earnings per share, SEK-0.42-0.70